The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Notification of Major Interest in Shares

2 Aug 2012 12:12

For filings with the FSA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying Silence Therapeutics plc issuer of existing shares to which voting rights are attached: ii

2 Reason for the notification (please tick the appropriate box or boxes):An acquisition or disposal of voting rightsAn acquisition or disposal of qualifying financial instruments which mayresult in the acquisition of shares already issued to which votingrights are attachedAn acquisition or disposal of instruments with similar economic effectto qualifying financial instrumentsAn event changing the breakdown of voting rightsOther (please specify):

3. Full name of person(s) subject to the Simpson Financial Limited notification obligation: iii

4. Full name of shareholder(s) (ifdifferent from 3.):iv5. Date of the transaction and date on 2 August 2012which the threshold is crossed orreached: v6. Date on which issuer notified: 2 August 20127. Threshold(s) that is/are crossed or below 3%

reached: vi, vii

8. Notified details:

A: Voting rights attached to shares viii, ixClass/type of Situation previous to Resulting situation after the triggeringshares if the triggering transactionpossible using transactionthe ISIN CODE Number of Number of Number of Number of voting % of voting rights Shares Voting shares rights x Rights Direct xi Direct Indirect Direct Indirect xiiGB0008433350 25,000,000 25,000,000 33,073,055 33,073,055 2.26%B: Qualifying Financial InstrumentsResulting situation after the triggering transactionType of financial Expiration Exercise/ Number of voting % of votinginstrument date xiii Conversion Period rights that may be rights xiv acquired if the instrument is exercised/ converted.N/AC: Financial Instruments with similar economic effect to Qualifying Financial Instrumentsxv, xviResulting situation after the triggering transactionType of Exercise Expiration Exercise/ Number of voting % of voting rightsfinancial price date xvii Conversion rights instrument xix, xxinstrument period refers to xviiiN/A Nominal Delta Total (A+B+C)Number of voting rights Percentage of voting rights33,073,055 2.26%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to holdvoting rights:13. Additional information:14. Contact name: Eric K. Simpson15. Contact telephone number: 852 2520 2066

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in sharesxxii

A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal Simpson Financial Limited entities) Contact address (registered office for Wyndham Place 26th Floor, 44 Wyndham legal entities)

Street, Central, Hong KongPhone number & email 852 2520 2066 sfl@simpsonfinancial.comOther useful information (at least legalrepresentative for legal persons)B: Identity of the notifier, if applicableFull nameContact addressPhone number & emailOther useful information (e.g. functionalrelationship with the person or legalentity subject to the notificationobligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
17th Feb 20217:00 amRNSFirst dosing for SLN360
15th Feb 20213:55 pmRNSHolding(s) in Company
15th Feb 20211:14 pmRNSHolding(s) in Company
12th Feb 20214:57 pmRNSHolding(s) in Company
12th Feb 20214:53 pmRNSHolding(s) in Company
12th Feb 202112:10 pmRNSAdditional Listing and Total Voting Rights
11th Feb 20215:29 pmRNSHolding(s) in Company
11th Feb 202111:06 amRNSHolding(s) in Company
8th Feb 20214:28 pmRNSAdditional listing and Total Voting Rights
5th Feb 20217:00 amRNSSilence Announces $45m Private Placement
29th Jan 20212:35 pmRNSAdditional listing and Total Voting Rights
25th Jan 202112:41 pmRNSAdditional listing and Total Voting Rights
7th Jan 20217:00 amRNSHoldings in Company
6th Jan 202111:08 amRNSGrant of Options
6th Jan 202110:08 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSBoard of Directors Appointment
6th Jan 20217:00 amRNSSilence Therapeutics Appoints Craig Tooman as CFO
5th Jan 20217:00 amRNSJanuary Conference Schedule
4th Jan 202111:45 amRNSHoldings in Company
15th Dec 202012:28 pmRNSHolding(s) in Company
4th Dec 20205:08 pmRNSAdditional listing and Total Voting Rights
3rd Dec 20209:45 amRNSDirector/PDMR Shareholding
3rd Dec 20209:44 amRNSDirector/PDMR Shareholding
17th Nov 20203:44 pmRNSAdditional listing and Total Voting Rights
16th Nov 20207:00 amRNSPositive pre-clinical data presented
2nd Nov 20207:00 amRNSSilence Therapeutics Appoints Dr. Marie Wikström
29th Oct 20204:41 pmRNSSecond Price Monitoring Extn
29th Oct 20204:36 pmRNSPrice Monitoring Extension
16th Oct 20202:05 pmRNSDirector/PDMR Shareholding
14th Oct 20201:15 pmRNSAdditional listing and Total Voting Rights
12th Oct 20203:49 pmRNSDirector/PDMR Shareholding
8th Oct 20207:00 amRNSChange to Executive Leadership Team
6th Oct 20204:25 pmRNSAdditional Listing and Total Voting Rights
1st Oct 20207:00 amRNSConference Participation
23rd Sep 20208:59 amRNSHolding(s) in Company
23rd Sep 20207:06 amRNSSecond Price Monitoring Extn
23rd Sep 20207:04 amRNSPrice Monitoring Extension
22nd Sep 20204:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20207:05 amRNSGrant of options
14th Sep 20207:00 amRNSSilence Therapeutics announces new CEO
14th Sep 20207:00 amRNS2020 interim results
8th Sep 20207:01 amRNSR&D update
8th Sep 20207:00 amRNSInstructions exchanging ordinary shares for ADSs
8th Sep 20207:00 amRNSCompletion of Nasdaq listing
7th Sep 20205:47 pmRNSHolding(s) in Company
4th Sep 20202:18 pmRNSHolding(s) in Company
3rd Sep 20207:00 amRNSSilence to Participate in US Investor Conferences
1st Sep 20207:00 amRNSSilence Therapeutics Notice of Results
21st Aug 20207:00 amRNSSilence Therapeutics Files Registration with SEC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.